CHD — Church & Dwight Co., Inc.

Sentiment is cautiously neutral-to-positive. Q2 2026 revenue of $1.53B beat consensus by roughly $30M, but adjusted EPS of $0.89 missed by a penny and guidance was narrowed to $3.74-$3.81. The formal analyst consensus is Buy (18 Buy / 15 Hold / 1 Sell) with a target near $108.88, yet shares are already close to that level, and recent insider selling adds no urgency. The market is waiting for volume growth rather than pricing growth to justify further upside.

Revenue growth is stable but sluggish: Q2 2026 grew only 1.6% YoY, Q1 2026 was essentially flat at 0.2%, and prior quarters ranged from roughly 4% to 5%. Gross and operating margins have been broadly stable in the 16-20% range, with Q2 2026 operating margin at 18.1% versus 17.4% a year earlier. The Q4 2024 operating loss of -$91.5M is clearly a one-off distortion, not a structural deterioration. Free cash flow is healthy and accelerating: Q2 2026 FCF of $256.9M was up 23% YoY. This is a low-growth, high-cash-conversion defensive franchise, not an accelerating growth story.

Fair, not cheap. As of 2026-08-27, CHD trades at 32.8x trailing EPS, slightly below its 5-year average of 35.95x, and at about 27.1x forward EPS using consensus FY26 EPS of $3.78. Price-to-sales of 3.89x is roughly in line with its 5-year average of 3.99x, and the PEG of 0.72 looks reasonable on a growth-adjusted basis. The absolute multiple is a premium to the broader consumer staples group, so the stock is not a bargain, but it is also not egregiously expensive versus its own history.

The market is paying roughly 27x forward earnings for a company with low-single-digit revenue growth and stable margins - essentially full price for steady quality. The consensus target of $108.88 implies only modest upside, and the low target of $97 suggests real downside if earnings disappoint. If volume growth fails to reaccelerate, the multiple should compress toward the high-20s forward P/E, making the stock vulnerable to even small EPS misses. A clean beat with volume improvement could push it toward $113+; a guidance cut likely sends it toward $95-97.

As of 2026-08-27, RSI was 57.18, price was 1.12% above the 20-day SMA, 3.47% above the 50-day SMA, and 8.36% above the 200-day SMA. This is a healthy but not overbought uptrend. There is no low-risk dip-buy signal here; a pullback toward the $100-101 zone or the 50-day moving average would offer a better entry than chasing strength.

• Low-beta (0.47) defensive staples attract capital during macro uncertainty, supporting CHD's valuation premium.
• Higher-for-longer interest rates pressure the 1.2% dividend yield relative to cash and bonds, limiting multiple expansion.
• Persistent input-cost and supply-chain inflation continues to restrain gross margin, which sits at 45.6% TTM.
• Consumer trade-down and private-label competition could pressure volumes if household budgets tighten.
• FX and commodity volatility in the Specialty Products segment can create quarterly noise in reported results.

• Q3 2026 earnings in late October/early November - management guides EPS of $0.89; investors will watch volume growth and confirmation of FY26 EPS of $3.74-$3.81.
• A potential Fed rate-cutting cycle or renewed rotation into defensive staples could re-rate the stock above $110.
• Gross margin recovery if input costs ease and pricing holds, which would drop straight to EPS.

• Growth disappointment: top-line growth has been only 0-5%; any volume decline undermines the high multiple.
• Multiple compression: at 27x forward earnings, valuation already assumes steady compounding; rising rates or a rotation to cyclicals could compress staples multiples.
• Input-cost inflation or private-label price competition could squeeze margins and force guidance down.
• Insider selling and a low-ish dividend yield reduce the urgency for income-oriented holders.

CHD is a dependable, high-quality defensive compounder with stable brands, strong free cash flow, and a reasonable balance sheet, but the stock is already priced for steady success. With low-single-digit revenue growth and consensus upside of only ~6%, it is a hold or accumulate-on-weakness rather than a compelling buy at $102.34.

I applied a 29.0x forward P/E to consensus FY26 EPS of $3.78, roughly one turn below CHD's 5-year average P/E of 35.95x after adjusting for low-single-digit growth and higher rates. This yields $109.62, close to the analyst consensus target but independently derived from the company's own historical multiple range.